The Ozempic lawsuit 2026 landscape has reached a critical inflection point. As of August 2026, there is no global settlement in either the gastrointestinal-related MDL or the NAION lawsuits, there are 3,928 lawsuits in the Ozempic MDL, and none of these cases have gone to trial. A pivotal Rule 702 (Daubert) expert hearing is scheduled for September 2026, a brand-new MDL for vision-loss injuries has completed its Science Day, and the regulatory gap between the U.S. FDA and Europe’s EMA continues to fuel failure-to-warn claims. For injured patients and legal observers alike, this is the most consequential pharmaceutical mass tort currently in motion.
Where the Ozempic MDL Stands in August 2026: Case Counts and Court Structure
MDL 3094, formally styled In re GLP-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, was established in February 2024 in the Eastern District of Pennsylvania before Judge Karen Spencer Marston. What began as a few dozen coordinated claims has exploded into one of the fastest-growing pharmaceutical mass torts in recent memory. The JPML’s July 1, 2026 statistics report listed 3,848 actions pending in MDL 3094, up from 3,763 a month earlier — case counts, not docket entry numbers — as the MDL, which began with 37 actions when it was centralized in February 2024, has grown by more than a hundred new federal filings a month through 2026. As of August 2026, 3,928 cases are pending in MDL 3094 in the Eastern District of Pennsylvania.
The defendants named across these thousands of complaints are Novo Nordisk — manufacturer of Ozempic, Wegovy, Rybelsus, and Saxenda — and Eli Lilly, maker of Mounjaro, Zepbound, and Trulicity. Both companies have vigorously contested liability, and no global settlement framework has emerged from either defendant as of this writing. Vision-loss claims are not part of MDL 3094; in December 2025, the JPML created a separate proceeding, MDL No. 3163, for claims alleging NAION (non-arteritic anterior ischemic optic neuropathy) and other vision loss tied to GLP-1 drugs, a much smaller docket of approximately 146 pending actions as of July 1, 2026.
A second MDL — MDL 3163, addressing NAION vision-loss injuries — was created in December 2025 for claims that Ozempic use caused NAION (an eye stroke that can cause vision loss), and Judge Marston also oversees this Ozempic vision loss MDL in the Eastern District of Pennsylvania. The JPML rejected Eli Lilly’s request to fold the vision loss cases into the existing GLP-1 gastrointestinal injury MDL, instead creating a standalone docket, noting that a separate MDL would make case tracking easier and allow Judge Marston to determine the appropriate level of coordination between the two litigations herself. This dual-MDL structure means Judge Marston is now simultaneously managing two of the most scientifically complex pharmaceutical litigations in the federal court system.
What Injuries Are Being Alleged in the Ozempic Lawsuit 2026
Understanding the injury breakdown is essential context for anyone evaluating the Ozempic lawsuit 2026. According to court documents, gastroparesis is the most frequently listed injury in complaints filed as part of the GLP-1 product liability litigation. In a hearing on January 13, 2026, Novo Nordisk’s attorney gave a breakdown of injuries: 75% of the lawsuits listed gastroparesis/stomach paralysis in the complaint, 18% listed ileus, and 8% listed gallbladder complications.
| Injury Category | Share of Complaints | MDL |
|---|---|---|
| Gastroparesis (stomach paralysis) | ~75% | MDL 3094 |
| Ileus (intestinal obstruction) | ~18% | MDL 3094 |
| Gallbladder complications | ~8% | MDL 3094 |
| NAION (vision loss) | Separate MDL | MDL 3163 |
The connection between GLP-1 drugs and these injuries is mechanistic, not incidental. GLP-1 receptor agonists work by delaying gastric emptying to reduce appetite and slow digestion — the same biological action that plaintiffs allege becomes permanently debilitating when the drug causes the stomach to stop emptying food entirely, a condition known as gastroparesis. Plaintiffs allege that the GLP-1 drugs caused gastrointestinal injuries including gastroparesis (stomach paralysis), ileus, intestinal obstruction or pseudo-obstruction, ischemic bowel, pancreatitis, gallbladder injury, aspiration, micronutrient deficiency, and in some cases death — and that the manufacturers failed to adequately warn patients and physicians of those risks. Additionally, the FDA’s adverse-event reporting system has logged more than 88,000 complications from people taking Ozempic and similar GLP-1 drugs, including Mounjaro, Wegovy and Zepbound, since 2018.
The expanded injury landscape now firmly includes vision loss. NAION claims are about sudden vision loss, often permanent, from reduced blood flow to the optic nerve. While early momentum in the Ozempic litigation was built around gastroparesis allegations, many plaintiffs’ lawyers now see more promise in the NAION claims. The gastroparesis cases face headwinds around causation, preexisting conditions, and the challenges of proving long-term injury from a multifactorial gastrointestinal disorder, while the NAION claims offer a more direct and identifiable harm — sudden vision loss — that may present a clearer narrative to both judges and juries.
The August 2025 Gastroparesis Ruling and the September 2026 Rule 702 Hearing
Two pivotal rulings have defined the evidentiary battlefield for the Ozempic lawsuit 2026. The first was a landmark order from Judge Marston in August 2025. On August 15, 2025, Judge Karen Spencer Marston of the United States District Court for the Eastern District of Pennsylvania issued a 78-page memorandum that reshapes the legal requirements for gastroparesis claims involving GLP-1 receptor agonist medications. Judge Marston ruled that any plaintiffs claiming to have had drug-induced gastroparesis must have had a gastric emptying study properly performed at the time of diagnosis, the results of which confirmed delayed emptying. Acceptable diagnostic tests include scintigraphy, breath tests, or wireless motility capsule (WMC) studies — clinical impressions alone are no longer sufficient.
This ruling had immediate strategic consequences. The ruling narrows the plaintiff pool but strengthens the remaining cases, meaning firms must now focus on clients with documented gastric emptying studies while aggressively pursuing emerging NAION vision loss claims. The August 2025 gastroparesis ruling requiring gastric emptying study documentation remains in effect and continues to shape case eligibility in 2026.
The second pivotal milestone is upcoming: a Rule 702 (Daubert) expert hearing scheduled for September 10–18, 2026. The court has set a Rule 702 expert hearing for September 2026 addressing warnings, preemption, and general causation — this is not a bellwether trial but is rather the gatekeeping ruling that determines whether plaintiffs’ expert causation testimony is admissible at all. Opening briefs were due May 19, 2026; opposition and reply briefing runs through the summer; and the court has reserved September 10 through 18, 2026 for the Rule 702 hearing. In product-liability mass torts, the most consequential Daubert ruling addresses general causation — whether the substance at issue is capable of causing the alleged injury at the doses and exposure routes plaintiffs claim. Specific causation, whether this plaintiff’s injury was caused by this exposure, follows. The outcome of the September 2026 hearing will be the single most important legal development in this litigation to date.
Science Day for the NAION MDL: Vision Loss Claims Gain Scientific Momentum
On June 2, 2026, the NAION MDL reached a critical early milestone. The federal judge overseeing MDL 3163 involving alleged vision loss and blindness ordered attorneys to participate in a “Science Day” presentation, the purpose of which was to educate the court on the scientific issues surrounding GLP-1 medications and their alleged connection to non-arteritic anterior ischemic optic neuropathy (NAION). Judge Marston directed both plaintiffs and defendants to present non-adversarial scientific information to the court.
The scientific foundation underpinning NAION claims is substantial and growing. A 2024 study published in JAMA Ophthalmology found an increased risk of NAION for those taking semaglutide medications. NAION is a rare eye condition that causes sudden, often irreversible, blindness or vision loss in one eye. Critically, European regulators have already acted on this evidence. The EMA’s safety committee (PRAC) concluded its review of medicines containing semaglutide following concerns about a possible increased risk of developing NAION. After reviewing all available data, PRAC concluded that NAION is a very rare side effect of semaglutide, meaning it may affect up to 1 in 10,000 people taking the drug.
The EMA’s Pharmacovigilance Committee (PRAC) recommended adding NAION to European drug labels and advising patients to stop the medication if NAION is confirmed. NAION is NOT included in U.S. drug labels for Ozempic, Wegovy, or Rybelsus, and the FDA is reportedly evaluating whether action is required — a regulatory gap that is central to plaintiffs’ failure-to-warn claims. The next anticipated steps in MDL 3163 include master pleadings, Plaintiff Fact Sheet requirements, expert discovery, and development of a bellwether process.
FDA Label Changes, EMA Action, and the Regulatory Timeline in the Ozempic Lawsuit 2026
The FDA’s evolving label history for Ozempic is central to the failure-to-warn legal theory driving thousands of complaints. Key milestones include:
- September 2023: The FDA updated the warning label for Ozempic (semaglutide) due to post-approval user experiences, adding ileus — a severe gastrointestinal disorder — to the label.
- January 2025: The Ozempic label was modified indicating that Ozempic is “not recommended in patients with severe gastroparesis.” Critically, the updated label does not warn that Ozempic can itself cause gastroparesis.
- October 2025: The FDA further updated the Ozempic label to emphasize gastrointestinal adverse reactions, and explicitly added that “OZEMPIC is not recommended in patients with severe gastroparesis,” while also adding intestinal obstruction and severe constipation to the adverse reactions section.
Plaintiffs argue that each of these label updates — coming years after adverse events began accumulating — demonstrates that Novo Nordisk had or should have had knowledge of these risks long before warnings were updated. The FDA’s adverse-event reporting system has logged more than 88,000 complications from people taking Ozempic and similar GLP-1 drugs since 2018.
The NAION label gap represents the sharpest regulatory fault line of 2026. In June 2025, the European Medicines Agency (EMA) officially confirmed that NAION is a “very rare” side effect of semaglutide drugs, recommending urgent updates to product labeling and treatment protocols. NAION is a leading cause of vision loss in adults and the second most common optic neuropathy after glaucoma; it typically presents as sudden, painless, monocular vision loss accompanied by optic disc edema, with vision loss that is generally irreversible and for which there is currently no effective treatment available. The FDA has not yet matched the EMA’s action, and NAION is NOT included in U.S. drug labels for Ozempic, Wegovy, or Rybelsus, with the FDA reportedly still evaluating whether action is required.
Bellwether Trials, Parallel State Litigation, and the Road to Resolution
No Ozempic case has gone to trial as of August 2026, and no bellwether trial date has been formally set. Bellwether selection and the first test trials would realistically follow the September 2026 Rule 702 hearing and summary-judgment rulings, putting any first GLP-1 trial in 2027 at the earliest if the litigation survives those rulings — meaning the MDL’s next inflection point is a set of court rulings, not a jury verdict, and those rulings could drastically narrow, reshape, or strengthen the litigation before any case is tried. Bellwether trials are currently expected to begin in late 2026 or early 2027, but these dates may change.
In an MDL, the court selects a small number of representative cases, called bellwether cases, to go to trial first. These trials test the strength of both sides’ arguments, reveal how juries respond, and typically catalyze global settlement negotiations. The bellwether process in MDL 3094 is underway as of 2026, making the next 12 to 24 months critically important for this litigation.
Parallel state court proceedings are adding structural pressure to both defendants. In addition to the federal MDL, a substantial number of GLP-1 lawsuits have been filed in New Jersey state courts — permitted because Novo Nordisk, the manufacturer of Ozempic and Wegovy, maintains its U.S. headquarters in New Jersey. The NJ state court proceedings are organized as multicounty litigations (MCLs) — one for gastrointestinal injury claims and a separate MCL for NAION vision loss claims. The New Jersey Supreme Court determined that NAION-related GLP-1 lawsuits in New Jersey state courts will be handled separately from the gastrointestinal injury cases.
Some legal scholars think settlement negotiations for the Ozempic cases could begin in 2027, though this is purely speculative. No settlement has been announced in MDL 3094, no class has been certified, and there is no claim form — the litigation is still in pretrial expert and summary-judgment proceedings, with the Rule 702 hearing scheduled for September 10 through 18, 2026.
Frequently Asked Questions About the Ozempic Lawsuit 2026
How many Ozempic lawsuits are pending in 2026?
The Ozempic MDL now has 3,928 pending cases as of August 2026. As of July 1, 2026, there are also 146 pending claims in MDL 3163, the NAION vision-loss MDL. There are also two Multicounty Litigations pending in New Jersey State Court — one focusing on gastrointestinal problems and the other pertaining to vision loss. The combined federal and state dockets make this one of the largest active pharmaceutical litigations in the country.
What injuries qualify for the Ozempic lawsuit in 2026?
Typical eligibility criteria for filing an Ozempic lawsuit in 2026 include having taken Ozempic or another semaglutide drug (Wegovy or Rybelsus) for weight loss or other treatment purposes, and having developed a condition such as stomach paralysis (for which you will need to present a gastric emptying test), gastric stasis, or intestinal obstructions. Additional qualifying injuries include cyclic vomiting syndrome (CVS); ileus and intestinal obstruction requiring emergency surgical intervention; pancreatitis alleged to be linked to GLP-1 receptor agonist use; gallbladder disease, including cholecystitis and cases where gallbladder removal was required; and acute kidney injury where severe dehydration from vomiting led to documented kidney damage. Vision loss associated with NAION also qualifies, as does a blood clot or pulmonary embolism after taking Ozempic. Claimants generally must have been hospitalized, visited the emergency room, or consulted with a gastroenterologist, and must have been under 75 years of age when they started taking the drug.
Has there been any Ozempic lawsuit settlement in 2026?
As of July 2026, no Ozempic or GLP-1 settlements have been reached and no cases have gone to verdict — every dollar figure discussed in legal projections is based on how comparable pharmaceutical mass torts resolved, not a reported Ozempic outcome. Settlement discussions will not meaningfully begin until after bellwether trials provide both sides with jury feedback on liability and damages. There is no settlement, no certified class, and no claim form — anyone promising a settlement payout right now is not describing this litigation accurately. Law firms are actively accepting GLP-1 injury cases as individual injury lawsuits filed in the MDL, not submitted as a claim form.
What is the NAION vision-loss MDL and how is it different from MDL 3094?
MDL No. 3163 is centralized in the Eastern District of Pennsylvania and is being handled before Judge Karen S. Marston — the same judge overseeing the gastrointestinal injury litigation. The separate MDL structure reflects the different medical evidence, expert testimony, causation issues, and injury mechanisms involved in NAION claims compared to gastroparesis, bowel obstruction, and other gastrointestinal injury cases. The European Medicines Agency acted first, adding NAION as a “very rare” side effect in June 2025, and this regulatory gap is central to plaintiffs’ failure-to-warn claims in MDL 3163. The NAION lawsuits remain in their early stages.
Who can file an Ozempic lawsuit in 2026?
Not all patients who took semaglutide will be eligible for compensation. To be eligible, you must have taken Ozempic or another GLP-1 drug — including Wegovy, Mounjaro, Zepbound, Trulicity, Saxenda, or Rybelsus — and have suffered a severe health condition. Filing an Ozempic lawsuit requires gastric emptying studies (not just symptoms) to prove gastroparesis claims, complete prescription records showing medication use dates, and medical documentation establishing that your injuries developed during or shortly after taking GLP-1 medications. State statutes of limitations for Ozempic lawsuits typically range from two to three years from when you discovered your injury, making prompt legal action necessary to preserve your right to seek compensation for medication-related injuries. Consulting with a qualified mass tort attorney is the essential first step, as eligibility is determined case by case based on specific medical documentation.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.